drugset / Trial / NCT00917839

The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00917839

Phase 2 Unknown 88 enrolled Cantonal Hospital of St. Gallen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the neuroprotective effect of lamotrigine in the combination of interferon beta 1a once weekly intramuscular in patients with relapsing-remitting multiple sclerosis.

Timeline

Start
2009-06
Primary completion
2010-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule 100 mg Oral